Deepak Aggarwal1, Varinder Saini1 and Ashok
Medicine, Govt Medical College & Hospital, Chandigarh, India
Response to chemotherapy in advance lung cancer is measured by serial
contrast enhanced computed tomography (CT) of thorax, using Response
Evaluation Criteria in Solid Tumours (RECIST ). However, CT does not
tell about functional status of the patient that seems more relevant.
Spirometry is a potential monitoring test that has not been tested
The present study was planned to evaluate spirometry as a monitoring
tool in advanced lung cancer patients on chemotherapy.
It was a prospective observational study on 40 lung cancer patients.
Tumor burden using RECIST criteria and spirometry (FEV1, FVC and
FEV1/FVC) were calculated at baseline and after 4 cycles of
chemotherapy. Change in spirometry values was compared with CT score
for possible association.
Squamous cell carcinoma was the commonest histological type (40%).
There was statistically significant improvement in the RECIST score
(mean change: -2.48 1.55 cm, 95% confident interval: -3.36
-1.60; P value <0.001) after 4 cycles. However, both
FEV1 and FVC marginally decreased (mean change in FEV1 -0.08
0.24 litres; P value 0.06 and mean change in FVC -0.04
0.28 litre; p value 0.39). Baseline RECIST score strongly
correlated with the change in RECIST score (correlation coefficient:
0.7, P value <0.001).
in the tumor burden as measured by serial CT does not reciprocate into
improvement in lung function.
Image : https://ecssafety.com/...